Craig Perlman, DO
Endocrinology, Diabetes & Metabolism · Bethpage, NYNPI 1750566402
Payments from drug & device makers
Across 1,313 payments — averaging $52.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$20K
- AstraZeneca$16K
- Lilly USA, LLC$7K
- Intuity Medical Inc$6K
- Sanofi-aventis U.S. LLC$2K
- Dexcom, Inc.$2K
- plus $16K from 54 others
What the payments were for
- Consulting fees$2,9254%
- Speaking & faculty fees$36,61353%
- Travel & lodging$6751%
- Food & beverage$28,52941%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$22,451
- FARXIGA$13,948
- Pogo Automatic Blood Glucose Monitoring System$5,381
- CeQur Simplicity$685
- DEXCOM G6 TRANSMITTER$584
- iLet Bionic Pancreas$387
- Reltone 200 Mg$149
- GLYCATE$149
- Reltone 400 Mg$149
- REZDIFFRA$141
- MYCAPSSA$138
- GVOKE HYPOPEN$128
- Tirosint$127
- Licart$127
- FLECTOR$127
- EVENITY$123
- DEXCOM G7 GSS (161)$122
- GVOKE PFS$118
- TOUJEO$108
- Omnipod$102
How this compares
$68,862 in reported general payments places this provider in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 552 | $1,185,703 |
| MounjaroTirzepatide | 572 | $1,162,493 |
| JardianceEmpagliflozin | 556 | $751,237 |
| TrulicityDulaglutide | 352 | $689,431 |
| FarxigaDapagliflozin Propanediol | 273 | $367,375 |
| Tresiba Flextouch U-200Insulin Degludec | 143 | $188,897 |
| Tresiba Flextouch U-100Insulin Degludec | 235 | $168,670 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 91 | $136,588 |
| TradjentaLinagliptin | 91 | $119,632 |
| JanuviaSitagliptin Phosphate | 97 | $102,734 |
| RybelsusSemaglutide | 38 | $94,667 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 110 | $88,702 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 64 | $84,379 |
| ProliaDenosumab | 46 | $78,776 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 53 | $75,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog, Lyumjev | $6,797 | $1,933,635997 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $1,355 | $1,330,124670 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $20,231 | $1,071,646778 claims |
| AstraZenecaFarxiga | $15,920 | $367,375273 claims |
| MerckJanuvia | $279 | $102,73497 claims |
| AmgenProlia | $993 | $78,77646 claims |
| Cequr CorporationCequr Simplicity | $726 | $43,86593 claims |
| AbbVieSynthroid | $647 | $18,557245 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $507 | $11,553772 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Bethpage
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
- Robert SilverBrooklyn$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.